ethyl 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylate | 13436-14-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylate
• 英文别名: 3-Carbethoxy-6,7-dimethoxy-4-chinolinol；3-Carbethoxy-4-hydroxy-6.7-dimethoxyquinoline；4-hydroxy-6,7-dimethoxy-quinoline-3-carboxylic acid ethyl ester；4-Hydroxy-6,7-dimethoxy-chinolin-3-carbonsaeure-aethylester；6,7-dimethoxy-4-hydroxy-3-quinoline carboxylate ethyl ester；6,7-Dimethoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester；ethyl 6,7-dimethoxy-4-oxo-1H-quinoline-3-carboxylate
• CAS: 13436-14-1
• 化学式: C₁₄H₁₅NO₅
• 分子量: 277.277
• InChiKey: LMEHZFXGGDLYMH-UHFFFAOYSA-N

物化性质

• 熔点：
  280-283 °C
• 沸点：
  395.7±37.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylate 在 palladium on activated charcoal 氢气 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 26.0h， 生成 ethyl 6,7-dimethoxyquinoline-3-carboxylate
  参考文献：
  名称：

  Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p56lck

  摘要：

  A study was undertaken to prepare inhibitors of the lymphocyte protein-tyrosine kinase p56lck. Using the known p56lck inhibitor 3,4-dihydroxy-alpha-cyanocinnamamide (4) as a lead compound, bicyclic analogues were designed as conformationally constrained mimetics in which the phenyl ring and vinyl side chain of the cinnamamide are locked into a coplanar orientation. Such planarity was rationalized to be an important determinant for binding within a putative flat, cleftlike catalytic cavity. Bicyclic analogues were prepared using the naphthalene, quinoline, isoquinoline, and 2-iminochromene ring systems and examined for their ability to inhibit autophosphorylation of immunopurified p56lck. The most potent analogues were methyl 7,8-dihydroxyisoquinoline-3-carboxylate (12) (IC50 = 0.2 muM) and 7,8-dihydroxyisoquinoline-3-carboxamide (13) (IC50 = 0.5 muM). Inhibition by 12 was not competitive with respect to ATP. These compounds may represent important new structural motifs for the development of p56lck inhibitors.

  DOI：

  10.1021/jm00056a001
• 作为产物：
  描述：

  乙氧基甲叉丙二酸二乙酯 以 二苯醚 为溶剂， 生成 ethyl 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylate
  参考文献：
  名称：

  表皮生长因子受体激酶的4-Anilino-6,7-二烷氧基喹啉-3-甲腈抑制剂及其与4-anilino-6,7-二烷氧基喹唑啉抑制剂的生物立体关系。

  摘要：

  描述了表皮生长因子受体（EGF-R）激酶的一系列4-苯胺基-6，7-二烷氧基喹啉-3-甲腈抑制剂的合成和SAR。将3，4-二烷氧基苯胺与（乙氧基亚甲基）氰基乙酸乙酯缩合，然后热环化，区域特异性地得到6，7-二烷氧基-4-氧代-1，4-二氢喹啉-3-甲腈。氯化（POCl（3）），然后与取代的苯胺反应，提供了EGF-R激酶的4-苯胺基-6，7-二烷氧基喹啉-3-甲腈抑制剂。这些化合物的另一种合成方法是从3，4-二烷氧基苯甲酸甲酯开始。硝化然后还原（Fe，NH（4）Cl，MeOH-H（2）O），得到2-氨基-4,5-二烷氧基苯甲酸甲酯。使用DMF-乙缩醛形成formation，然后使用LiCH（2）CN环化，得到6,7-二烷氧基-4-氧代-1,4-二氢喹啉-3-腈 像以前一样进行了改造。还制备了在喹啉环的3-位上含有酸，酯，酰胺，甲醇和醛基的化合物，以及几种1-苯胺基-6,7-二甲氧基异喹啉-4

  DOI：

  10.1021/jm000206a

文献信息

• Substituted 3-cyano quinolines
  申请人：American Cyanamid Company

  公开号：US06002008A1

  公开（公告）日：1999-12-14

  This invention provides compounds having the formula: ##STR1## wherein: X is cycloalkyl which may be optionally substituted; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally substituted; n is 0-1; Y is --NH--, --O--, --S--, or --NR--; R is alkyl of 1-6 carbon atoms; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each, independently, hydrogen, halogen, alkyl, alkenyl, alkynyl, alkenyloxy, alkynyloxy, hydroxymethyl, halomethyl, alkanoyloxy, alkenoyloxy, alkynoyloxy, alkanoyloxymethyl, alkenoyloxymethyl, alkynoyloxymethyl, alkoxymethyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy, carboalkyl, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino, alkylamino, dialkylamino, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, phenylamino, benzylamino, ##STR2## R.sub.5 is alkyl which may be optionally substituted, or phenyl which may be optionally substituted; R.sub.6 is hydrogen, alkyl, or alkenyl; R.sub.7 is chloro or bromo R.sub.8 is hydrogen, alkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-cycloalkylaminoalkyl, N-cycloalkyl-N-alkylaminoalkyl, N,N-dicycloalkylaminoalkyl, morpholino-N-alkyl, piperidino-N-alkyl, N-alkyl-piperidino-N-alkyl, azacycloalkyl-N-alkyl, hydroxyalkyl, alkoxyalkyl, carboxy, carboalkoxy, phenyl, carboalkyl+, chloro, fluoro, or bromo; Z is amino, hydroxy, alkoxy, alkylamino, dialkylamino, morpholino, piperazino, N-alkylpiperazino, or pyrrolidino; m=1-4,q=1-3, and p=0-3; any of the substituents R.sub.1, R.sub.2, R.sub.3, or R.sub.4 that are located on contiguous carbon atoms can together be the divalent radical --O--C(R.sub.8).sub.2 --O--; or a pharmaceutically acceptable salt thereof with the proviso that when Y is --NH--, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are hydrogen, and n is 0, X is not 2-methylphenyl, which are inhibitors of protein tyrosine kinase.

  这项发明提供了具有以下结构的化合物：##STR1## 其中：X是环烷基，可以选择性地被取代；或者是吡啶基、嘧啶基或苯环；其中吡啶基、嘧啶基或苯环可以选择性地被取代；n为0-1；Y为--NH--、--O--、--S--或--NR--；R为1-6个碳原子的烷基；R.sub.1、R.sub.2、R.sub.3和R.sub.4分别独立地是氢、卤素、烷基、烯基、炔基、烯氧基、炔氧基、羟甲基、卤甲基、烷酰氧基、烯酰氧基、炔酰氧基、烷酰氧甲基、烯酰氧甲基、炔酰氧甲基、烷氧甲基、烷氧基、烷基硫、烷基亚砜基、烷基磺酰基、烷基磺酰胺基、烯基磺酰胺基、炔基磺酰胺基、羟基、三氟甲基、氰基、硝基、羧基、羧基烷氧基、羧基烷基、苯氧基、苯基、噻吩氧基、苄基、氨基、羟氨基、烷氧氨基、烷基氨基、二烷基氨基、氨基烷基、N-烷基氨基烷基、N,N-二烷基氨基烷基、苯基氨基、苄氨基、##STR2## R.sub.5是可以选择性取代的烷基，或者是可以选择性取代的苯基；R.sub.6是氢、烷基或烯基；R.sub.7是氯或溴；R.sub.8是氢、烷基、氨基烷基、N-烷基氨基烷基、N,N-二烷基氨基烷基、N-环烷基氨基烷基、N-环烷基-N-烷基氨基烷基、N,N-二环烷基氨基烷基、吗啉-N-烷基、哌啶-N-烷基、N-烷基-哌啶-N-烷基、氮杂环烷基-N-烷基、羟基烷基、烷氧基烷基、羧基、羧基烷氧基、苯基、羧基+、氯、氟或溴；Z是氨基、羟基、烷氧基、烷基氨基、二烷基氨基、吗啉基、哌嗪基、N-烷基哌嗪基或吡咯烷基；m=1-4，q=1-3，p=0-3；任何位于相邻碳原子上的R.sub.1、R.sub.2、R.sub.3或R.sub.4取代基可以共同形成二价基团--O--C(R.sub.8).sub.2 --O--；或其药学上可接受的盐，但当Y为--NH--时，R.sub.1、R.sub.2、R.sub.3和R.sub.4为氢，n为0时，X不是2-甲基苯基，这些化合物是蛋白酪氨酸激酶的抑制剂。
• Method of treating or inhibiting colonic polyps
  申请人：American Cyanamid Company

  公开号：US06384051B1

  公开（公告）日：2002-05-07

  This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula 1 wherein: R1, R2, R3, R4, X, Y, and n are as defined hereinbefore, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗或抑制结肠息肉的方法，包括提供如下公式1的化合物： 其中： R1、R2、R3、R4、X、Y和n如前文所定义，或其药用可接受的盐。
• Substituted 3-cyanoquinolines
  申请人：American Cyanamid Company

  公开号：US06288082B1

  公开（公告）日：2001-09-11

  This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

  这项发明提供了具有结构的化合物I的公式，其中G1、G2、R1、R4、Z、n和X在规范中定义，或其药用盐，这些化合物可用作抗肿瘤剂，并用于多囊肾病的治疗。
• 4(1H)-quinolone derivatives
  申请人：——

  公开号：US05081121A1

  公开（公告）日：1992-01-14

  Quinolone derivatives having a quinolone structure: ##STR1## where Yo is O or S are disclosed, which are useful as cardiotonic agents. Typical examples of the quinolone derivatives include: 6,7-dimethoxy-4 (1H) quinolone (compound 6) and 5-hydroxy-6-methoxy-4(1H) quinolone (compound 1) as typical compounds of the formulae[I] and [I'], respectively, shown in the specification.

  具有喹诺酮结构的喹诺酮衍生物被披露，其中Yo是O或S，这些衍生物可用作心力衰竭药物。喹诺酮衍生物的典型例子包括：6,7-二甲氧基-4(1H)喹诺酮（化合物6）和5-羟基-6-甲氧基-4(1H)喹诺酮（化合物1），它们分别是规范中显示的公式[I]和[I']的典型化合物。
• 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
  申请人：Pharmacia & Upjohn Company

  公开号：US06093732A1

  公开（公告）日：2000-07-25

  The present invention provides 4-hydroxyquinoline-3-carboxamide and hydrazide compounds of formula I ##STR1## These compounds are useful to treat or prevent the herpesviral infections, particularly, human cytomegaloviral infection.

  本发明提供了式I的4-羟基喹啉-3-甲酰胺和肼化合物。这些化合物可用于治疗或预防疱疹病毒感染，特别是人类巨细胞病毒感染。